NASDAQ:ONVO Organovo (ONVO) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free ONVO Stock Alerts $1.11 +0.06 (+5.71%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.05▼$1.2450-Day Range$0.90▼$1.1452-Week Range$0.89▼$2.33Volume848,993 shsAverage Volume60,339 shsMarket Capitalization$11.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Organovo alerts: Email Address Organovo MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.50% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.74) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.18 out of 5 starsMedical Sector809th out of 947 stocksBiological Products, Except Diagnostic Industry138th out of 159 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Organovo. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.50% of the outstanding shares of Organovo have been sold short.Short Interest Ratio / Days to CoverOrganovo has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Organovo has recently decreased by 63.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOrganovo does not currently pay a dividend.Dividend GrowthOrganovo does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONVO. Previous Next 3.3 News and Social Media Coverage News SentimentOrganovo has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Organovo this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for ONVO on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows3 people have added Organovo to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Organovo insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Organovo is held by insiders.Percentage Held by InstitutionsOnly 9.14% of the stock of Organovo is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Organovo are expected to grow in the coming year, from ($1.74) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organovo is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Organovo is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrganovo has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency About Organovo Stock (NASDAQ:ONVO)Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Read More ONVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONVO Stock News HeadlinesMarch 17, 2024 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.comMarch 9, 2024 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Research Coverage Started at StockNews.comMarch 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 24, 2024 | benzinga.comOrganovo Holdings Stock (NASDAQ:ONVO) Earnings Dates and Earning CallsFebruary 10, 2024 | finance.yahoo.comOrganovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagFebruary 9, 2024 | morningstar.comOrganovo Holdings Inc ONVOFebruary 9, 2024 | finance.yahoo.comONVO Continues ProgressFebruary 8, 2024 | sfgate.comOrganovo: Fiscal Q3 Earnings SnapshotMarch 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 8, 2024 | msn.comOrganovo Holdings Unveils Corporate Presentation OnlineJanuary 25, 2024 | finance.yahoo.comOrganovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis CongressJanuary 9, 2024 | finance.yahoo.comOrganovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis CongressDecember 7, 2023 | finanznachrichten.deOrganovo, Inc.: Organovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsDecember 6, 2023 | finance.yahoo.comOrganovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsNovember 13, 2023 | msn.comOVNO Continues Developing Breakthrough TreatmentsNovember 13, 2023 | finance.yahoo.comCORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and PlanNovember 11, 2023 | finance.yahoo.comOrganovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)November 8, 2023 | finance.yahoo.comOrganovo Highlights FXR314 Combination Therapy Potential and PlanNovember 7, 2023 | msn.comONVO, FATH and BYU among mid-day moversOctober 10, 2023 | finance.yahoo.comONVO: A Company With Great Technology to Impact Health CareSeptember 8, 2023 | finance.yahoo.comOrganovo to Participate in the H.C. Wainwright Global Investment ConferenceAugust 25, 2023 | finance.yahoo.comIs Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapAugust 23, 2023 | finance.yahoo.comOrganovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 DataAugust 16, 2023 | msn.comOnvo receives $3 million grant from PennDOT to enhance electric vehicle charging infrastructureJuly 29, 2023 | seekingalpha.comONVO Organovo Holdings, Inc.July 20, 2023 | msn.comOnvo introduces first public fast electric vehicle chargers on I-81 stretchJune 7, 2023 | fool.comOrganovo (NASDAQ: ONVO)See More Headlines Receive ONVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today3/18/2024Fiscal Year End3/31/2024Next Earnings (Estimated)7/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ONVO CUSIPN/A CIK1497253 Webwww.organovo.com Phone(858) 224-1000FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,260,000.00 Net Margins-4,061.12% Pretax Margin-7,885.54% Return on Equity-182.88% Return on Assets-138.52% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual Sales$370,000.00 Price / Sales30.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book0.63Miscellaneous Outstanding Shares10,040,000Free Float9,638,000Market Cap$11.14 million OptionableOptionable Beta0.90 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Keith E. Murphy (Age 52)Company Secretary & Executive Chairman Comp: $626.24kMs. Vaidehi Joshi (Age 38)Director of Discovery Biology & Director Comp: $91.4kMr. Thomas P. Hess CPA (Age 60)MBA, President & CFO Dr. Curtis M. Tyree Ph.D.Senior Vice President of Strategy & Business DevelopmentKey CompetitorsBioCardiaNASDAQ:BCDAGenetic TechnologiesNASDAQ:GENEPHAXIAM TherapeuticsNASDAQ:PHXMEiger BioPharmaceuticalsNASDAQ:EIGRCreative Medical TechnologyNASDAQ:CELZView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 73,788 shares on 3/11/2024Ownership: 3.522%Vanguard Group Inc.Bought 73,788 shares on 2/15/2024Ownership: 3.522%Simplex Trading LLCBought 300 shares on 2/2/2024Ownership: 0.000%David GobelSold 19,607 sharesTotal: $31,763.34 ($1.62/share)View All Insider TransactionsView All Institutional Transactions ONVO Stock Analysis - Frequently Asked Questions How have ONVO shares performed in 2024? Organovo's stock was trading at $1.11 at the start of the year. Since then, ONVO stock has increased by 0.0% and is now trading at $1.11. View the best growth stocks for 2024 here. Are investors shorting Organovo? Organovo saw a drop in short interest in the month of February. As of February 29th, there was short interest totaling 150,400 shares, a drop of 63.0% from the February 14th total of 407,000 shares. Based on an average daily trading volume, of 161,000 shares, the short-interest ratio is currently 0.9 days. View Organovo's Short Interest. When is Organovo's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024. View our ONVO earnings forecast. How were Organovo's earnings last quarter? Organovo Holdings, Inc. (NASDAQ:ONVO) issued its quarterly earnings results on Thursday, February, 8th. The medical research company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.01. The medical research company earned $0.01 million during the quarter, compared to the consensus estimate of $0.08 million. Organovo had a negative net margin of 4,061.12% and a negative trailing twelve-month return on equity of 182.88%. When did Organovo's stock split? Organovo shares reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Taylor Crouch's approval rating as Organovo's CEO? 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Organovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK). Who are Organovo's major shareholders? Organovo's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.52%), Vanguard Group Inc. (3.52%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Gobel and Douglas Jay Cohen. View institutional ownership trends. How do I buy shares of Organovo? Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONVO) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.